Axxcess Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Axxcess Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$17K	Buy	+17,790	New	+$19.7K	﹤0.01%	977

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Axxcess Wealth Management's LCTX Position: Q3 2026 in Review

Axxcess Wealth Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 17,790 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #977 among its holdings.

61 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Axxcess Wealth Management held 17,790 shares of Lineage Cell Therapeutics worth $17K as of Q3 2026.
Lineage Cell Therapeutics was a new Axxcess Wealth Management position in Q3 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Axxcess Wealth Management's portfolio in Q3 2026, its #977 holding.
61 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Axxcess Wealth Management's 13F filing for Q3 2026, filed 21 Oct 2026.